-
Mashup Score: 11FOMO No Mo! | ASH Clinical News | American Society of Hematology - 4 month(s) ago
Aaron Gerds, MD, is the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute and associate professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. In recent months, people have started leaving X (formerly known as Twitter) because of several factors, one of which is a growing general dissatisfaction with the platform. During a recent meeting of the American Society of Hematology’s Committee on Communications, we discussed why hematologists
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Program Director Resources - 4 month(s) ago
With the goal of providing the highest quality educational tools to tomorrow’s oncologists, ASCO offers programming for oncology training for Program Directors. In addition, ASCO provides opportunities for Program Directors to connect with one another and share information and resources about the Accreditation Council for Graduate Medical Education (ACGME) and ACGME
Source: society.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Join me and @basneta16 for a discussion with other fellowship program leaders at the next @ASCO Quarterly Connection on August 27 at 3pm ET where we will be discussing best practices and tips & tricks to maximize the ASCO-SEP digital subscription. https://t.co/hBeyeLe8OO
-
-
Mashup Score: 13Expert Insights on Important Updates in Multiple Myeloma With Marc Braunstein, MD, PhD - 5 month(s) ago
In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @targetedonc for the opportunity to review updates on #CAR T-cell therapy in #myeloma. #mmsm @Perlmutter_CC https://t.co/0VYIUmIRvI https://t.co/sNQt70xfIA
-
-
Mashup Score: 12Expert Insights on Important Updates in Multiple Myeloma With Marc Braunstein, MD, PhD - 5 month(s) ago
In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @targetedonc for the opportunity to review updates on #CAR T-cell therapy in #myeloma. #mmsm @Perlmutter_CC https://t.co/0VYIUmIRvI https://t.co/sNQt70xfIA
-
-
Mashup Score: 11The Process of Fellowship Applications Demystified - 5 month(s) ago
It’s July/August of the year and this is the time when new residents and fellows start their new chapter of their lives.BUT: How do they get here. In this sp…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @chadinabhan and @heMEGirl_MD for a great discussion on the fellowship application process, and inital steps toward becoming a #hematologist/#oncologist. @nyulisom @NYULISOM_HemOnc @Perlmutter_CC https://t.co/ToYtQGmZyj https://t.co/JGWugvxo9E
-
-
Mashup Score: 4Podcast: Novel Approaches in Hematologic Malignancies at ASCO24 - 7 month(s) ago
Drs. John Sweetenham and Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple myeloma, and the 7-year analysis of the ECHELON-1 trial in classical Hodgkin lymphoma.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Always a pleasure to speak with Dr. John Sweetenham @JSweetenhamMD on the @ASCO #ascodailynews podcast about updates on hematologic maligancies from #ASCO24 @Perlmutter_CC https://t.co/OcV5CiTvPO
-
-
Mashup Score: 4SYMPATICO Results Support Concurrent Ibrutinib and Venetoclax in TP53-Mutated Mantle Cell Lymphoma - 7 month(s) ago
Concurrent ibrutinib and venetoclax demonstrated high complete response rates and durable remission in patients with TP53-mutant MCL (Abstract 7007). Although ibrutinib was voluntarily withdrawn from FDA accelerated approval in previously treated MCL, the improved efficacy of the combination can be applied across alternative BTK inhibitors.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Thank you to @ASCO for the opporunity to comment in #ascodailynews on encouraging data from #ASCO24 using #ibrutinib in TP53-mutated mantle cell #lymphoma as shown in the SYMPATICO study #MCL @Perlmutter_CC https://t.co/tLDiGEVP0N
-
-
Mashup Score: 4Asciminib Shows Superiority Over Available Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia - 7 month(s) ago
Results from the phase 3 ASC4FIRST study demonstrate the superiority of asciminib over other standard-of-care frontline tyrosine kinase inhibitors in the treatment of newly diagnosed chronic myeloid leukemia (LBA6500).
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hematologists1Tweet-
Glad to have the opportunity to comment in @ASCO #ascodailynews on encouraging data from #ASCO24 using #asciminib upfront in #CML @Perlmutter_CC https://t.co/Mt3O77b3sL
-
-
Mashup Score: 2Journal of Clinical Oncology - 7 month(s) ago
The 2024 ASCO Annual Meeting Proceedings – Hematologic Malignancies Abstracts Edition is a listing of all accepted abstracts from the hematologic malignancies track of the 2024 ASCO Annual Meeting.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Here is a helpful listing of the #ASCO24 abstracts on hematologic malignancies https://t.co/UxmqrA5QL7
-
-
Mashup Score: 7From Diagnosis to Empowerment: The Evolution of The Patient Story - 8 month(s) ago
I am joined today on Healthcare Unfiltered by Stephanie Chuang, a remarkable patient advocate, survivor of non-Hodgkin lymphoma, and the visionary behind The…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
I really enjoy the interviews with @chadinabhan at @podcastunfilter, including this excellent one with patient advocate @StephChuang on supporting patients and oncologists through the #cancer journey and beyond, including a discussion about #lymphoma. https://t.co/mK3g9Bf19d
-
Given the many conferences, research, and other avnues to dive deeper into work in oncology, it's natural to have #FOMO (fear of missing out). This is a nice editorial by @AaronGerds on reassessing goals. "Recognize that your career is not a competition." https://t.co/Mtzl2uBGM0